The findings which were published in Science Immunology identifies new links between the course of the disease and a patient’s immune response to it. SARS-CoV-2 binds to human cells via a structure on its surface called the spike protein. Current vaccine candidates use portions of the spike protein to stimulate an immune response. Finally, they assessed the effectiveness of the antibodies in preventing the spike protein from binding to ACE2 in a laboratory dish. It remains to be seen whether the immune response to SARS-CoV-2 vaccination is stronger, or persists longer than that caused by natural infection.

Source: Hindustan Times December 26, 2020 09:38 UTC